BACKGROUND: This study aimed to investigate the outcome of patients with advanced gastrointestinal stromal tumors (GISTs) exhibiting focal disease progression during imatinib therapy, treated by surgical resection and imatinib continuation. METHODS: A consecutive series of 38 patients with metastatic GISTs who underwent treatment with imatinib at our centers during a defined period of time was evaluated. Patients were evaluated for demographics including tumor-related features, initial response, disease recurrence, and salvage treatment modalities, and were classified as having either focal or generalized progression upon presentation prior to salvage therapy. RESULTS: After a median follow-up of 31.8 months, 25 of the 38 (65.8%) patients had progressed. Nine (36%) patients were classified as having focal and 16 (64%) as having generalized progression. Salvage therapies were: surgical resection and imatinib dose escalation in patients exhibiting focal progression and imatinib dose escalation alone in the majority of patients exhibiting generalized progression. Focal progression was associated with prolonged progression-free survival (PFS) and overall survival (OS) after salvage therapy as compared with generalized progression (median PFS and OS, 11.3 months and not attained, versus 2.5 and 22.8 months, respectively). Six-month PFS was 89% and 39% in patients exhibiting focal and generalized progression, respectively. KIT mutation analysis of controlled and progressive lesions was performed in 4 patients with focal progression. Secondary KIT mutations affected progressive lesions, whereas nonprogressive lesions harbored the original mutations only. CONCLUSION: Patients with advanced GIST exhibiting focal disease progression during imatinib therapy may benefit from surgical resection and imatinib continuation. Imatinib resistance seems to be partial in these patients.
BACKGROUND: This study aimed to investigate the outcome of patients with advanced gastrointestinal stromal tumors (GISTs) exhibiting focal disease progression during imatinib therapy, treated by surgical resection and imatinib continuation. METHODS: A consecutive series of 38 patients with metastatic GISTs who underwent treatment with imatinib at our centers during a defined period of time was evaluated. Patients were evaluated for demographics including tumor-related features, initial response, disease recurrence, and salvage treatment modalities, and were classified as having either focal or generalized progression upon presentation prior to salvage therapy. RESULTS: After a median follow-up of 31.8 months, 25 of the 38 (65.8%) patients had progressed. Nine (36%) patients were classified as having focal and 16 (64%) as having generalized progression. Salvage therapies were: surgical resection and imatinib dose escalation in patients exhibiting focal progression and imatinib dose escalation alone in the majority of patients exhibiting generalized progression. Focal progression was associated with prolonged progression-free survival (PFS) and overall survival (OS) after salvage therapy as compared with generalized progression (median PFS and OS, 11.3 months and not attained, versus 2.5 and 22.8 months, respectively). Six-month PFS was 89% and 39% in patients exhibiting focal and generalized progression, respectively. KIT mutation analysis of controlled and progressive lesions was performed in 4 patients with focal progression. Secondary KIT mutations affected progressive lesions, whereas nonprogressive lesions harbored the original mutations only. CONCLUSION:Patients with advanced GIST exhibiting focal disease progression during imatinib therapy may benefit from surgical resection and imatinib continuation. Imatinib resistance seems to be partial in these patients.
Authors: Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Hohenberger; Isabelle Ray-Coquard; Marcus Schlemmer; Allan T van Oosterom; David Goldstein; Raf Sciot; Pancras C W Hogendoorn; Michelle Brown; Rossella Bertulli; Ian R Judson Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Elena Tamborini; Elisa Gabanti; M Stefania Lagonigro; Tiziana Negri; Silvana Pilotti; Marco A Pierotti; Sabrina Pricl Journal: Cancer Res Date: 2005-02-01 Impact factor: 12.701
Authors: Christopher L Corless; Arin Schroeder; Diana Griffith; Ajia Town; Laura McGreevey; Patina Harrell; Sharon Shiraga; Troy Bainbridge; Jason Morich; Michael C Heinrich Journal: J Clin Oncol Date: 2005-05-31 Impact factor: 44.544
Authors: Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson Journal: Lancet Date: 2004 Sep 25-Oct 1 Impact factor: 79.321
Authors: Lei L Chen; Jonathan C Trent; Elsie F Wu; Gregory N Fuller; Latha Ramdas; Wei Zhang; Austin K Raymond; Victor G Prieto; Caroline O Oyedeji; Kelly K Hunt; Raphael E Pollock; Barry W Feig; Kimberly J Hayes; Haesun Choi; Homer A Macapinlac; Walter Hittelman; Marco A Velasco; Shreyaskumar Patel; Michael A Burgess; Robert S Benjamin; Marsha L Frazier Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Beverly S Schaffer; Eri Taniguchi; Aoife Kilcoyne; Amanda T McCleish; Laura D Nelon; Francis G Giles; Argiris Efstratiadis; Robin D LeGallo; Brent M Nowak; Brian P Rubin; Suman Malempati; Charles Keller Journal: Mol Cancer Ther Date: 2011-03-29 Impact factor: 6.261
Authors: A C M van de Luijtgaarden; J W J de Rooy; L F de Geus-Oei; W T A van der Graaf; W J G Oyen Journal: Cancer Imaging Date: 2008-10-04 Impact factor: 3.909